AstraZeneca's COVID-19 vaccine still has a role to play in the fight against the pandemic, even as sales slow and the company charges more in some places, CEO Pascal Soriot said on Friday, the latest drugmaker to warn about a global supply glut.
In the first quarter, the company recorded $1.15 billion in sales for the product, the majority of which came from initial contracts, but that number eclipsed analysts' consensus forecast of $739 million, cited by Credit Suisse.
Apart from the vaccine, AstraZeneca also has a COVID-19 treatment, Evusheld, which has been authorised in many regions including the United States, United Kingdom and European Union for preventing infections in people whose immune system is too weak to respond to vaccines. "It's a sad situation, quite frankly, because people who are immunocompromised are really suffering from the COVID crisis."
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Covid-19: NI care home relatives call for answers on Covid testsFamilies ask why untested hospital patients were sent to care homes at the start of the pandemic.
Read more »
Moderna Asks FDA to Approve Its COVID-19 Shot for Kids Under 6Moderna on Thursday asked U.S. regulators to authorize low doses of its COVID-19 vaccine for children younger than 6, a long-awaited move toward potentially opening shots for millions of tots by summer.
Read more »
How Gilead is positioning Veklury against COVID-19 antivirals like PaxlovidThe company has an oral version of its COVID-19 drug Veklury in a clinical trial.
Read more »
Shareholder Proposals to Broaden Access to Covid-19 Vaccines RejectedInvestors voted down shareholder proposals urging Pfizer, Moderna and Johnson & Johnson to broaden access to their Covid-19 vaccines
Read more »